Revuforj/Revumenib (SNDX-5613) + Mezigdomide (CELMod) (Menin Inhibitor)

May 12, 2026 — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced that 12 abstracts on Revuforj® (revumenib), its oral first-in-class menin inhibitor, were released on the European Hematology Association (EHA) website ahead of the EHA 2026 Congress (June 11–14, 2026; Stockholm). The abstracts span real-world and clinical-trial datasets across acute leukemia subtypes including KMT2A-rearranged (KMT2Ar), NPM1-mutated (NPM1m), and NUP98-rearranged (NUP98r) disease.

Highlighted presentations include: interim real-world ROAR study findings in relapsed/refractory (R/R) acute leukemia; updated Phase 1 frontline revumenib + intensive chemotherapy data in AML with KMT2Ar/NPM1m/NUP98r; post–hematopoietic stem cell transplant (HSCT) maintenance outcomes and a post hoc AUGMENT-101 post-transplant analysis; updated SAVE trial results combining revumenib with venetoclax and decitabine/cedazuridine in R/R disease; and activity in R/R NUP98r acute leukemia (AUGMENT-101 and expanded access).

Syndax stated these datasets show strong activity, deep responses including MRD negativity, robust transplant rates, and favorable tolerability, supporting ongoing pivotal combination trials and potential paradigm expansion in AML.